Anticancer Efficacy of Self-Nanoemulsifying Drug Delivery System of Sunitinib Malate
- 337 Downloads
Sunitinib malate (SM) is reported as a weakly soluble drug in water due to its poor dissolution rate and oral bioavailability. Hence, in the current study, various “self-nanoemulsifying drug delivery systems (SNEDDS)” of SM were prepared, characterized and evaluated for the enhancement of its in vitro dissolution rate and anticancer efficacy. On the basis of solubilization potential of SM in various excipients, “Lauroglycol-90 (oil), Triton-X100 (surfactant) and Transcutol-P (cosurfactant)” were selected for the preparation of SM SNEDDS. SM-loaded SNEDDS were developed by spontaneous emulsification method, characterized and evaluated for “thermodynamic stability, self-nanoemulsification efficiency, droplet size, polydispersity index (PDI), zeta potential (ZP), surface morphology, refractive index (RI), the percent of transmittance (% T) and drug release profile.” In vitro dissolution rate of SM was significantly enhanced from an optimized SNEDDS in comparison with SM suspension. The optimized SNEDDS of SM with droplet size of 42.3 nm, PDI value of 0.174, ZP value of −36.4 mV, RI value of 1.339, % T value of 97.3%, and drug release profile of 95.4% (after 24 h via dialysis membrane) was selected for in vitro anticancer efficacy in human colon cancer cells (HT-29) by MTT assay. MTT assay indicated significant anticancer efficacy of optimized SM SNEDDS against HT-29 cells in comparison with free SM. The results of this study showed the great potential of SNEDDS in the enhancement of in vitro dissolution rate and anticancer efficacy of poorly soluble drug such as SM.
KEY WORDSanticancer efficacy dissolution droplet size SNEDDS sunitinib malate
“This project was supported by Deanship of Scientific Research, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia (Project No.5657/03/2016)”.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 1.Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327–37.PubMedGoogle Scholar
- 15.Khattab A, Hassanin L, Zaki N. Self-nanoemulsifying drug delivery system of coenzyme (Q10) with improved dissolution, bioavailability, and protective efficiency on liver fibrosis. APPS Pharm Sci Tech. doi: 10.1208/s12249-016-0632-x.
- 37.Jubeli E, Yagoubi N, Pascale F, Bédouet L, Slimani K, Labarre D, et al. Embolization biomaterial reinforced with nanotechnology for an in-situ release of anti-angiogenic agent in the treatment of hyper-vascularized tumors and arteriovenous malformations. Eur J Pharm Biopharm. 2015;96:396–408.CrossRefPubMedGoogle Scholar
- 39.Higuchi T, Connors KA. Phase-solubility techniques. Adv Anal Chem Instr. 1965;4:117–22.Google Scholar
- 44.United States Pharmacopeia (USP) XXIV, 2003. US Pharmacopeial Convention, CD Rom version.Google Scholar
- 47.Nuchuchua O, Sakulku U, Uawongyart N, Puttipipatkhachorn S, Soottitantawat A, Ruktanonchai U. In vitro characterization and mosquito (Aedes aegypti) repellent activity of essential-oils-loaded nanoemulsions. AAPS Pharm Sci Tech. 2009;10:1234–42.Google Scholar
- 52.Shakeel F, Alanazi FK, Raish M, Haq N, Radwan AA, Alsarra IA. Pharmacokinetic and in vitro cytotoxic evaluation of cholesterol-rich nanoemulsion of cholesteryl-succinyl-5-fluorouracil. J Mol Liq. 2015;211:164–8.Google Scholar